Movement Alert｜BeiGene Rises 4.18% in Regular Trading, Technical Rebound After Consecutive Declines Combined With New Drug Approval Boost

Market Focus06-04

On June 4, BeiGene (06160.HK) rose 4.18% in regular trading, trading at 172.3 HKD/share, with trading volume of HKD 144 million.

The stock had previously declined approximately 10% over three consecutive trading sessions, primarily dragged down by Baker Bros. Advisors LP's reduction of approximately USD 190 million in holdings and sustained weakness in the innovative drug sector. On the positive side, BeiGene announced on May 29 that Antaishi (tarlatamab for injection) received NMPA approval for second-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in adult patients who have failed one prior systemic therapy including platinum-based chemotherapy. Clinical data from the DeLLphi-304 study demonstrated a 40% reduction in the risk of death, with median overall survival extended by 5.3 months to 13.6 months compared to standard chemotherapy. The broader biotech sector stabilized on the day, with previously oversold stocks staging a technical rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153174514?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153174514","market":"us","top_or_hot":-1,"title":"Movement Alert｜BeiGene Rises 4.18% in Regular Trading, Technical Rebound After Consecutive Declines Combined With New Drug Approval Boost","media":"Market Focus","content":"<p><p>On June 4, BeiGene (06160.HK) rose 4.18% in regular trading, trading at 172.3 HKD/share, with trading volume of HKD 144 million.</p><p>The stock had previously declined approximately 10% over three consecutive trading sessions, primarily dragged down by Baker Bros. Advisors LP's reduction of approximately USD 190 million in holdings and sustained weakness in the innovative drug sector. On the positive side, BeiGene announced on May 29 that Antaishi (tarlatamab for injection) received NMPA approval for second-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in adult patients who have failed one prior systemic therapy including platinum-based chemotherapy. Clinical data from the DeLLphi-304 study demonstrated a 40% reduction in the risk of death, with median overall survival extended by 5.3 months to 13.6 months compared to standard chemotherapy. The broader biotech sector stabilized on the day, with previously oversold stocks staging a technical rebound.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BeiGene Rises 4.18% in Regular Trading, Technical Rebound After Consecutive Declines Combined With New Drug Approval Boost</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BeiGene Rises 4.18% in Regular Trading, Technical Rebound After Consecutive Declines Combined With New Drug Approval Boost\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, BeiGene (06160.HK) rose 4.18% in regular trading, trading at 172.3 HKD/share, with trading volume of HKD 144 million.</p><p>The stock had previously declined approximately 10% over three consecutive trading sessions, primarily dragged down by Baker Bros. Advisors LP's reduction of approximately USD 190 million in holdings and sustained weakness in the innovative drug sector. On the positive side, BeiGene announced on May 29 that Antaishi (tarlatamab for injection) received NMPA approval for second-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in adult patients who have failed one prior systemic therapy including platinum-based chemotherapy. Clinical data from the DeLLphi-304 study demonstrated a 40% reduction in the risk of death, with median overall survival extended by 5.3 months to 13.6 months compared to standard chemotherapy. The broader biotech sector stabilized on the day, with previously oversold stocks staging a technical rebound.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1153174514","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153174514","pubTimestamp":1780537227,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, BeiGene (06160.HK) rose 4.18% in regular trading, trading at 172.3 HKD/share, with trading volume of HKD 144 million.The stock had previously declined approximately 10% over three...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"运动快讯|百济神州常规交易涨4.18%连跌后技术性反弹叠加新药审批提振","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On June 4, BeiGene (06160.HK) rose 4.18% in regular trading, trading at 172.3 HKD/share, with trading volume of HKD 144 million.The stock had previously declined approximately 10% over three consecutive trading sessions, primarily dragged down by Baker Bros. Advisors LP's reduction of approximately USD 190 million in holdings and sustained weakness in the innovative drug sector. On the positive side, BeiGene announced on May 29 that Antaishi (tarlatamab for injection) received NMPA approval for second-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in adult patients who have failed one prior systemic therapy including platinum-based chemotherapy. Clinical data from the DeLLphi-304 study demonstrated a 40% reduction in the risk of death, with median overall survival extended by 5.3 months to 13.6 months compared to standard chemotherapy. The broader biotech sector stabilized on the day, with previously oversold stocks staging a technical rebound.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153174514","isCrawlerRequest":true}